# Re-evaluation Task: TN-007

## Context
- **Case ID**: TN-007
- **Cancer type**: HPV-Positive Oropharyngeal Squamous Cell Carcinoma (Base of Tongue)
- **Stage**: T2N1M0, AJCC 8th Edition Stage I (p16-positive)
- **Molecular profile**: HPV-positive (p16+), Non-smoker, PD-L1 CPS likely >=20 (favorable for immunotherapy), 45-year-old male
- **Report file**: experiment_reports\TN-007_report.json
- **Current score**: 84/100
- **Gap analysis (local GPU)**: The most critical gaps in the TN-007 cancer research report include the lack of data on Perioperative Pembrolizumab (KEYNOTE-689 Regimen) and OPTIMA-II: Neoadjuvant Nivolumab + Chemotherapy, which will improve the score by providing more comprehensive information on immunotherapies and targeted therapies. Filling these gaps with specific data will enhance the report's credibility and provide valuable insights for researchers, clinicians, and patients, ultimately leading to improved treatment outcomes and better decision-making in cancer care.

## Current dimension scores
| Dimension | Score | % of max |
|---|---|---|
| evidence_depth                      |  11/25  |  44.0% |
| clinical_relevance                  |   9/10  |  90.0% |
| rating_calibration                  |  14/15  |  93.3% |
| structural_integrity                |  15/15  | 100.0% |
| tier_coverage                       |  10/10  | 100.0% |
| source_quality                      |  15/15  | 100.0% |
| combo_supportive_coverage           |  10/10  | 100.0% |

## Target dimension: `evidence_depth` (44.0% of max)

## Your instructions

Read the full report JSON at `experiment_reports\TN-007_report.json`.

Your task: Fill missing evidence fields in `treatments[].key_evidence`.

For each treatment where these are null or missing, search and fill:
- `key_evidence.study_name` — full trial name
- `key_evidence.year` — publication year
- `key_evidence.sample_size` — numeric patient count
- `key_evidence.os_months.treatment` — median OS in treatment arm (months)
- `key_evidence.os_months.control` — median OS in control arm (months)
- `key_evidence.os_months.hazard_ratio` — HR from primary analysis
- `key_evidence.os_months.p_value` — p-value from OS analysis
- `key_evidence.pfs_months.treatment` — median PFS treatment arm
- `key_evidence.pfs_months.control` — median PFS control arm

Rules:
- Only fill with data you can verify from published trials
- Set to null (not omit) if genuinely unavailable after searching
- Do NOT fabricate or estimate numbers

Return the corrected `treatments` array only.

## Output format

Return a valid JSON object containing ONLY the corrected section (e.g., `{"treatments": [...]}` or `{"sources": [...]}`).

Do NOT return the full report — only the corrected array. The runner will merge it back.

After returning the JSON, add one line:
`SCORE_IMPACT: <estimated new score>/100`

## Report JSON (for reference)

```json
{
  "report_metadata": {
    "generated_date": "2026-03-23",
    "cancer_type": "HPV-Positive Oropharyngeal Squamous Cell Carcinoma (Base of Tongue)",
    "stage": "T2N1M0, AJCC 8th Edition Stage I (p16-positive)",
    "molecular_profile": [
      "HPV-positive (p16+)",
      "Non-smoker",
      "PD-L1 CPS likely >=20 (favorable for immunotherapy)",
      "45-year-old male"
    ]
  },
  "treatments": [
    {
      "rank": 1,
      "name": "Cisplatin + Concurrent Radiation (70 Gy IMRT) — Standard Definitive CRT",
      "category": "Standard of Care",
      "composite_rating": 9.2,
      "rating_breakdown": {
        "evidence_level": {
          "score": 10,
          "rationale": "Phase III RCT data from NRG-HN005 (2024), RTOG 1016, and De-ESCALaTE HPV. NRG-HN005 showed 98.1% 2-year PFS and 99% 2-year OS for standard CRT arm in favorable-risk HPV+ OPSCC, establishing this as the definitive benchmark."
        },
        "survival_benefit": {
          "score": 10,
          "rationale": "Exceptional outcomes for Stage I HPV+ OPSCC: 2-year PFS 98.1%, 2-year OS 99% (NRG-HN005). 5-year OS exceeds 90% for non-smoking HPV+ patients. De-escalation arms (60 Gy) failed noninferiority, confirming 70 Gy CRT superiority."
        },
        "accessibility": {
          "score": 10,
          "rationale": "Universally available at all oncology centers. Cisplatin and IMRT are standard infrastructure. NCCN Category 1 recommendation. No specialized equipment beyond standard linear accelerators required."
        },
        "safety_profile": {
          "score": 5,
          "rationale": "Significant acute toxicities: grade 3-4 mucositis (40-60%), dysphagia requiring feeding tube (27-40%), cisplatin-related nephrotoxicity, ototoxicity, myelosuppression. Long-term xerostomia and swallowing dysfunction common. Manageable but impactful for young survivors."
        },
        "biomarker_match": {
          "score": 10,
          "rationale": "HPV+ tumors show exquisite radiosensitivity. Non-smoker status further improves prognosis. No specific biomarker requirement beyond p16 positivity confirming HPV-driven disease."
        }
      },
      "mechanism_of_action": "Cisplatin forms DNA crosslinks causing apoptosis and acts as a radiosensitizer by inhibiting DNA repair mechanisms. Combined with 70 Gy IMRT delivered in 33-35 fractions over 7 weeks, this exploits the enhanced radiosensitivity of HPV-positive tumors. High-dose cisplatin (100 mg/m2 q3w x 2-3 cycles) provides systemic micrometastatic coverage.",
      "key_evidence": {
        "study_name": "NRG Oncology HN005",
        "journal": "ASTRO Annual Meeting / Journal of Clinical Oncology",
        "year": 2024,
        "sample_size": 382,
        "os_months": {
          "treatment": 0,
          "control": 0,
          "hazard_ratio": 0,
          "p_value": 0
        },
        "pfs_months": {
          "treatment": 0,
          "control": 0
        },
        "orr_percent": {
          "treatment": 98,
   
... (truncated — read full file from experiment_reports\TN-007_report.json)
```
